1 / 6

Uveitis Therapeutics Pipeline Analysis - Clinical Trials, Results, Designation & Collaboration

Uveitis Therapeutics Pipeline Analysis by Stages, Drug Class, Company Profile, Phase of Development, Clinical Trial, Preclinical Research & Discovery Stage Insights.

NidhiNehani
Télécharger la présentation

Uveitis Therapeutics Pipeline Analysis - Clinical Trials, Results, Designation & Collaboration

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Uveitis Therapeutics Pipeline to Witness Numerous Technological Advancements in the Coming Years

  2. Uveitis Therapeutics Pipeline According to a new research report “Uveitis Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments” published by P&S Market Research, Uveitis currently exhibits a pipeline with 33 drug candidates. Explore Report Description at: https://www.psmarketresearch.com/market-analysis/uveitis-therapeutics-pipeline-analysis Uveitis therapeutics pipeline in 2017 The study analyzed that the uveitis therapeutics pipeline comprises 33 drug candidates in different stages of development. Uveitis is a type of inflammatory disease that causes swelling and destroys eye tissues. Occurrence of this disease can result in slight reduction of vision or lead to complete vision loss. Uveitis occurs when the middle layer of the eyeball gets inflamed (red and swollen). This layer, known as the uvea, has many blood vessels that nourish the eye. Uveitis can damage vital eye tissue, even resulting in permanent vision loss.

  3. Uveitis Therapeutics Pipeline Durasert technology platform for Uveitis drug development pSivida Corp. is using durasert technology platform for the development of Medidur for the treatment of uveitis. This technology platform is used to provide sustained, localized delivery of drugs to the back of the eye. Durasert products are developed with a drug core surrounded with one or more polymer layers, the permeability of those layers and other aspects of the design of the product, controls the rate and duration of the drug release. However, changing the elements of the design, can help in altering both the rate and duration of release to meet different therapeutic needs. The later generation durasert products and product candidates are injected at the target site, while early generations were surgically implanted.

  4. Uveitis Therapeutics Pipeline Various companies received grants for the development of Uveitis Therapeutics Pipeline Many companies are involved in the development of drugs for the uveitis therapeutics pipeline, with their products in different phases. Some of the key players developing drugs for the treatment of uveitis include Aldeyra Therapeutics, Inc., EyeGate Pharmaceuticals, Inc., pSivida Corp. and others.

  5. Uveitis Therapeutics Pipeline Download report sample at: https://www.psmarketresearch.com/market-analysis/uveitis-therapeutics-pipeline-analysis/report-sample

  6. GET IN TOUCH THANK YOU! For information regarding permissions and other queries Kindly write to: US/Canada Toll-Free: 1-888-778-7886

More Related